Back to top
more

Cambrex Corporation (CBM)

(Delayed Data from NYSE)

$46.20 USD

46.20
398,613

+2.73 (6.28%)

Updated May 3, 2019 04:02 PM ET

After-Market: $46.20 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Zacks.com featured highlights: Braskem S.A., Cambrex, FutureFuel and Gibraltar Industries

Zacks.com featured highlights: Braskem S.A., Cambrex, FutureFuel and Gibraltar Industries

    Juno Gets Breakthrough Therapy Status for Lymphoma Drug

    Juno Therapeutics, Inc. (JUNO) and partner Celgene Corporation (CELG), announced that the FDA has granted Breakthrough Therapy designation to their investigational candidate, JCAR017.

      ACADIA Phase II Alzheimer's Drug Hits Primary Endpoint

      ACADIA Pharmaceuticals Inc. (ACAD) announced that a phase II exploratory study (-019 Study) evaluating pimavanserin for the treatment of Alzheimer's disease psychosis (AD Psychosis) met the primary endpoint.

        4 Stocks Riding High on Increasing Cash Flow

        Achieving profit is no doubt a company's goal, but having healthy cash flow is imperative to its existence, development and success.

          J&J Files for FDA Approval of Simponi Aria Label Expansion

          Johnson & Johnson's (JNJ), Janssen submitted two sBLAs in the U.S. seeking approval of Simponi Aria for the treatment of psoriatic arthritis and ankylosing spondylitis.

            Biogen (BIIB) Board Okays Hemophilia Business Spin-off

            Biogen (BIIB) announced that its board of directors has approved the spin-off of its hemophilia business into a new company Bioverativ Inc.

              Amgen Files for Approval of Osteoporosis Drug in Japan

              Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that they have submitted an application seeking marketing approval for its investigational monoclonal antibody romosozumab to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

                AbbVie (ABBV) Submits NDA for Next-Gen HCV Combo in US

                AbbVie Inc. (ABBV) announced that it has submitted a New Drug Application (NDA) to the FDA for its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).

                  Zacks.com featured highlights: Braskem SA, Cambrex, Gibraltar Industries, State National and Leucadia National

                  Zacks.com featured highlights: Braskem SA, Cambrex, Gibraltar Industries, State National and Leucadia National

                    Conatus Stock Up on Liver Drug Collaboration with Novartis

                    Conatus (CNAT) inked an exclusive option, collaboration and license agreement with Novartis (NVS) for the worldwide development and commercialization of emricasan.

                      Bet On These 5 Stocks with Striking Net Profit Margin

                      There is no better metric than net profit margin when it comes to determining a company's profit level.

                        Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data

                        Pfizer, Inc. (PFE) announced that the FDA has lifted a boxed warning about neuropsychiatric side effects from the label of its smoking cessation drug, Chantix.

                          Zacks.com featured highlights: Coherent, Applied Materials, Cambrex, McDermott International and EnerSys

                          Zacks.com featured highlights: Coherent, Applied Materials, Cambrex, McDermott International and EnerSys

                            Intercept (ICPT) Ocaliva Gains Conditional Approval in EU

                            Intercept (ICPT) Ocaliva, in combination with UDCA, was approved in the EU for the treatment of PBC.

                              Zacks.com featured highlights: Applied Materials, Cambrex, Cirrus Logic, Daktronics and Seagate Technology

                              Zacks.com featured highlights: Applied Materials, Cambrex, Cirrus Logic, Daktronics and Seagate Technology

                                7 Stocks Near 52-Week Highs to Buy Right Now

                                Over the past few decades, trading got more challenging with a rising number of investment strategies flooding the markets.

                                  Kite Pharma Enters into Partnership with Vitruvian Networks

                                  Kite Pharma (KITE) entered into a strategic partnership with Vitruvian Networks to create a software solution to support commercial availability of T-cell therapies.

                                    Repros to Meet with the FDA for Phase III Proellex Program

                                    Repros (RPRX) announced that it has requested a meeting with the FDA to discuss requirements for phase III development of Proellex.

                                      Novartis Offers Positive Data on Breast Cancer Drug LEE011

                                      Novartis (NVS) announced results from the phase III MONALEESA-2 study on LEE011 for the treatment of first-line HR+/HER2- advanced breast cancer.

                                        Endo (ENDP) Inks Deal to Return Belbuca Rights to BioDelivery

                                        Endo (ENDP) announced that it has entered into an agreement to return the rights for Belbuca to BioDelivery (BDSI).

                                          Zacks.com featured highlights: Big 5 Sporting Goods, Cambrex and Children's Place

                                          Zacks.com featured highlights: Big 5 Sporting Goods, Cambrex and Children's Place

                                            AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting

                                            AstraZeneca plc (AZN) presented positive data from a randomized phase III study (AURA3) on its lung cancer drug Tagrisso at a lung cancer conference in Vienna, Austria.

                                              Is Cooper Companies (COO) Poised for Earnings Beat in Q4?

                                              The Cooper Companies Inc. (COO) is set to report fourth-quarter fiscal 2016 results after the market closes on Dec 8.

                                                Sage Therapeutics Stock Up on SAGE-547 Regulatory Update

                                                Sage (SAGE) announced expedited development plan on SAGE-547 following receipt of formal meeting minutes from a breakthrough therapy meeting with the FDA.

                                                  Juno Reports Positive Phase I Study Data on Lymphoma Drug

                                                  Juno Therapeutics, Inc. (JUNO) announced encouraging preliminary clinical data from a phase I study (TRANSCEND) on its lead pipeline candidate, JCAR017, for the treatment of patients non-Hodgkin lymphoma (NHL).